GlassScriptPhysician profile
Vanessa Arguello Schmidt
NPI 1588949176
$387.59
in general payments reported to CMS, 2019-2025
12 companies · $374 in 2025
The $374 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.69 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $373.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $72.72 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $43.41 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $42.41 | 2025 | Twiist |
| Novo Nordisk INC | $40.15 | 2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $31.99 | 2025 | Airsupra |
| Dexcom, INC. | $31.93 | 2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $31.74 | 2025 | Vowst |
| Bayer Healthcare Pharmaceuticals INC. | $25.43 | 2025 | |
| Mannkind Corporation | $22.24 | 2025 | |
| Xeris Pharmaceuticals, INC. | $17.26 | 2025 | Gvoke Hypopen |
| Corcept Therapeutics | $14.62 | 2025 | Korlym |
| Insulet Corporation | $13.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.